Merck
CN

Chronic angle-closure glaucoma related to paroxetine treatment.

Seminars in ophthalmology (2013-05-01)
M A Sierra-Rodriguez, F Saenz-Frances, E Santos-Bueso, J Garcia-Feijoo, J C Gonzelez-Romero
摘要

To present a unique case of a 33-year-old woman using paroxetine who presented with acute unilateral visual loss due to chronic angle-closure glaucoma. Case report. A 33-year-old women who had been under paroxetine treatment for the past four months presented at the emergency room due to a sudden loss of visual acuity (VA) in the left eye (LE). Narrow anterior chamber was detected. Intraocular pressure (IOP) was 29 mmHg right eye (RE) and 42 mm Hg LE. A fundus exam revealed a cup-to-disc ratio of 0.9-1 for the LE and of 0.1-0.2 for the RE. Paroxetine treatment was suspended, and after 48 h IOP was 10 mm Hg in both eyes (BE). ND-YAG laser iridotomy was performed in BE. In the subsequent visit, IOP was 25 mm Hg in the RE and 41 mm Hg in the LE; on her own initiative the patient had resumed paroxetine treatment. After requesting the patient again to stop taking the anti-depressant, IOP was 10 mm Hg in BE in the next exam 48 h later. As far as we are aware, there are no other reports of chronic angle-closure glaucoma related to the use of paroxetine. We thus consider that, before initiating treatment with this drug, patients should be informed of its potential ocular risks and they should be subjected to an ophthalmologic examination before its use is authorized.

材料
货号
品牌
产品描述

Sigma-Aldrich
帕罗西汀 盐酸盐 半水合物, ≥98% (HPLC), powder
Supelco
Paroxetine maleate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
帕罗西汀 马来酸盐, ≥98% (HPLC), solid
帕罗西汀 盐酸盐 半水合物, European Pharmacopoeia (EP) Reference Standard
帕罗西汀, European Pharmacopoeia (EP) Reference Standard